-

09:21:42 PM

LIVE Real Time VXRT Stock Market News

VXRT - Vaxart Inc

05/07/21 8:00 AM

Nasdaq : VXRT

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly -- there currently is no approved vaccine Safety and immunogenicity data to also inform oral COVID-19 vaccine program in older population SOUTH

RHEA-AI

negative

05/04/21 8:00 AM

Nasdaq : VXRT

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study results may inform the COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE

RHEA-AI

neutral

05/03/21 5:06 PM

Nasdaq : VXRT

New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

RHEA-AI

neutral

05/03/21 8:00 AM

Nasdaq : VXRT

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/II Four clinical trials of the oral norovirus vaccine candidate to be initiated in 2021 Cash, cash equivalents, and

RHEA-AI

negative

04/29/21 8:00 AM

Nasdaq : VXRT

Vaxart to Present at the World Vaccine Congress Washington 2021

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean

RHEA-AI

neutral

04/26/21 8:00 AM

Nasdaq : VXRT

Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant

RHEA-AI

negative

04/23/21 8:00 AM

Nasdaq : VXRT

Vaxart Appoints David Wheadon, M.D., to its Board of Directors

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon, M.D., to its Board

RHEA-AI

neutral

04/22/21 8:00 AM

Nasdaq : VXRT

Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans

Nearly 19 million more American adults - about a

RHEA-AI

very negative

03/04/21 4:01 PM

Nasdaq : VXRT

Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwright

RHEA-AI

neutral

02/25/21 4:01 PM

Nasdaq : VXRT

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021 Cash and cash equivalents of $126.9 million as of December 31, 2020 Conference call and webcast focused on our COVID-19 strategy scheduled for Tuesday, March 2,

RHEA-AI

negative